Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.36 |
| ▸ | CHRNG | P07510 | 2/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.36 |
| ▸ | CHRND | Q07001 | 2/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18715649 | 0.90 | GLP1R (0.54) | GLP1RLPAR3LPAR1TLR2FOLH1 | |
| SCHEMBL22404807 | 0.90 | GLP1R (0.54) | GLP1RLPAR3LPAR1TLR2CHRNA1 | |
| SCHEMBL20814382 | 0.89 | GLP1R (0.47) | GLP1RLPAR3LPAR1TLR2CHRNA1 | |
| SCHEMBL20375678 | 0.89 | GLP1R (0.53) | GLP1RLPAR3LPAR1TLR2CHRNA1 | |
| SCHEMBL20800966 | 0.89 | GLP1R (0.52) | GLP1RLPAR3LPAR1TLR2CHRNA1 | |
| SCHEMBL20375509 | 0.88 | GLP1R (0.53) | GLP1RLPAR3LPAR1TLR2CHRNA1 | |
| SCHEMBL22566714 | 0.86 | GLP1R (0.44) | GLP1RLPAR3LPAR1TLR2CHRNA1 | |
| SCHEMBL23714552 | 0.85 | GLP1R (0.51) | GLP1RLPAR3LPAR1TLR2CHRNA1 | |
| SCHEMBL23714526 | 0.84 | GLP1R (0.50) | GLP1RLPAR3LPAR1TLR2CHRNA1 | |
| SCHEMBL22453873 | 0.84 | GLP1R (0.48) | GLP1RLPAR3LPAR1TLR2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11590156-B2 | RNAi agents for hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| US-11517584-B2 | RNAi agents for Hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2022-12-06 | — | — | US | disclosed |
| US-11492624-B2 | RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1 | Arrowheads Pharmaceuticals, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220170015-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220056454-A1 | RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-02-24 | — | — | US | disclosed |
| US-20210395745-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210100829-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2021-04-08 | — | — | US | disclosed |
| US-20200330499-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | Janssen Pharmaceuticals, Inc. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200283777-A1 | RNAi Agents And Compositions for Inhibiting Expression of Asiaglycoprotein Receptor 1 | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-09-10 | — | — | US | disclosed |
| US-20200263179-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-08-20 | — | — | US | disclosed |
| US-20190255091-A1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056454-A1 | RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use | HSD17B13, HSD17B3, HSD17B10 | GLP1R 3037/4885LPAR3 1424/4885LPAR1 1985/4885 |
| US-11590156-B2 | RNAi agents for hepatitis B virus infection | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885LPAR3 549/4885LPAR1 389/4885 |
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885LPAR3 549/4885LPAR1 389/4885 |
| US-11492624-B2 | RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1 | ASGR1, LDLR, SCARB1 | GLP1R 217/4885LPAR3 150/4885LPAR1 62/4885 |
| US-20210100829-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885LPAR3 549/4885LPAR1 389/4885 |
| US-20210395745-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, NR1H4 | GLP1R 3941/4885LPAR3 559/4885LPAR1 320/4885 |
| US-20200283777-A1 | RNAi Agents And Compositions for Inhibiting Expression of Asiaglycoprotein Receptor 1 | ASGR1, LDLR, SCARB1 | GLP1R 405/4885LPAR3 125/4885LPAR1 55/4885 |
| US-20200330499-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION | HAVCR2, HCCS, EIF2AK2 | GLP1R 4386/4885LPAR3 1483/4885LPAR1 1221/4885 |
| US-11517584-B2 | RNAi agents for Hepatitis B virus infection | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885LPAR3 549/4885LPAR1 389/4885 |
| US-20190255091-A1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885LPAR3 549/4885LPAR1 389/4885 |
| US-20220170015-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885LPAR3 3281/4885LPAR1 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.